XTLB

XTL Biopharmaceuticals Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website xtlbio.com
Employees(FY) -
ISIN US98386D3070

Performance

-5.35%

-15.18%

-37.89%

-34.27%

+75.23%

YTD

+77.02%

Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Advanced Technical Analysis

Technical Analysis of XTLB 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance, and the Technical Score of 33 reinforces the bearish outlook. This combination implies that despite some oscillating momentum, the prevailing trend remains n...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of XTLB

Stock Rank

Recent News & Updates

2024-08-13 21:15
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million(Globenewswire)
2024-06-16 19:40
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-06-04 21:15
XTL Entered Definitive Agreement to Acquire The Social Proxy(Globenewswire)
2024-05-12 19:23
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-04-28 19:33
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-03-19 22:15
XTL To Aquire The Social Proxy(Globenewswire)
2023-10-20 04:00
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel(Globenewswire)
2023-10-20 04:00
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency(Globenewswire)
2018-11-20 19:00
Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications(Yahoo Finance)
2018-10-31 22:09
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update(Yahoo Finance)
2018-07-23 21:09
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update(Yahoo Finance)
2018-05-29 05:37
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update(Yahoo Finance)
2017-12-12 18:30
Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells(Yahoo Finance)
2017-12-05 23:08
XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements(Yahoo Finance)
2017-11-26 21:30
XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results(Yahoo Finance)
2017-10-22 23:23
XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements(Yahoo Finance)
2017-10-05 19:30
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy(Yahoo Finance)
2017-10-04 19:50
Earnings Review and Free Research Report: DelMar Missed Earnings Expectations(Yahoo Finance)
2017-09-25 21:23
XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-09-11 21:00
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome(Yahoo Finance)
2017-07-10 19:00
Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update(Yahoo Finance)
2017-06-14 21:00
XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-04-26 21:50
XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors(Yahoo Finance)
2017-04-04 21:10
XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome(Yahoo Finance)
2017-03-29 20:55
XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update(Yahoo Finance)
2017-03-21 21:22
XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors(Yahoo Finance)
2017-03-06 23:40
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors(Yahoo Finance)
2017-02-28 19:30
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement(Yahoo Finance)
2017-02-16 19:00
XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering(Yahoo Finance)
2017-02-12 20:08
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome(Yahoo Finance)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.